Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates

Published 04/25/2019, 11:48 PM
Updated 07/09/2023, 06:31 AM

Universal Health Services Inc. (NYSE:UHS) reported first-quarter 2019 adjusted earnings of $2.45 per share, missing the Zacks Consensus Estimate by 5.8%. Meanwhile, the bottom line matched the prior-year quarter’s figure on the back of revenue growth.

Results were impacted by a pre-tax unrealized loss of $4.3 million due to a decline in the market value of shares of certain marketable securities.

Net revenues increased 4.3% year over year to $2.8 billion, banking on higher admissions and patient days. However, the metric lagged the Zacks Consensus Estimate by 0.4%.

Total operating expenses of $2.5 billion at the end of the first quarter rose4.7% year over year, mainly due to salaries, wages and benefits along with other operating expense plus supplies expenses.

Universal Health Services, Inc. Price, Consensus and EPS Surprise

Segment Update

Acute Care Hospitals:


Adjusted admissions and adjusted patient days were up 4.9% and 4.4%, respectively, from the prior-year quarter. Net revenues (on a same facility basis) climbed 4.7% in the first quarter, majorly aided by a rise in admissions and patient days.

Behavioral Hospitals:

On same facility basis, adjusted admissions inched up 2.9% while adjusted patient days dipped 0.9%, both on a year-over-year basis. Net revenues were up 3% during the quarter under review on same facility basis.

Financial Update

As of Mar 31, 2019, the company had cash and cash equivalents of nearly $62.7 million, down 40.4% from the year-end 2018-level.

Total assets were $11.7 billion as of Mar 31, 2019, up 4.1% from the figure as of 2018 end.

The company’s long-term debt came in at $ 3.8 billion, down 2.9% from the number as of Dec 31, 2018.

For the first quarter, net cash provided by operating activities totaled $391 million, down 4.6% year over year due to an unfavorable change in accounts receivable as well as other combined adverse changes.

Buyback Program

During the first quarter, the company bought back shares worth $106.3 million.

Moreover, last December, its board of directors authorized a $500-million jump from the existing share repurchase program.

Zacks Rank

Universal Health currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Upcoming Releases From Medical Sector

Some stocks worth considering from the medical sector are as follows:

Aduro Biotech, Inc. (NASDAQ:ADRO) is slated to release first-quarter earnings figures on May 1. This stock has an Earnings ESP of +82.00% and a Zacks Rank #2 (Buy). You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

bluebird bio, Inc. (NASDAQ:BLUE) has an Earnings ESP of +12.12% and a Zacks Rank of 3. The company is set to report first-quarter earnings on May 1.

Humana Inc. (NYSE:HUM) is set to report first-quarter 2019 earnings performance on May 1. The stock has an Earnings ESP of +0.84% and a Zacks Rank of 3.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>



bluebird bio, Inc. (BLUE): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Universal Health Services, Inc. (UHS): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.